Clinical Trial Update: Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated a triple-drug regimen of bevacizumab, lenalidomide, and dexamethasone in relapsed or refractory Stage II/III multiple myeloma, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Avastin (bevacizumab)
• Decadron (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma in Relapse, Stage II Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-01